NCT00164424

Brief Summary

The purpose of this study is to determine if acyclovir episodic treatment has an effect in ulcer healing and if it should be added to the syndromic management of genital ulcer disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
613

participants targeted

Target at P75+ for phase_2 hiv-infections

Timeline
Completed

Started Mar 2005

Longer than P75 for phase_2 hiv-infections

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2005

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2005

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 14, 2005

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
2.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
Last Updated

September 11, 2012

Status Verified

September 1, 2012

Enrollment Period

4 years

First QC Date

September 9, 2005

Last Update Submit

September 10, 2012

Conditions

Keywords

HSV2genital ulcerHIVSouth AfricaTreatmentAcyclovirPrevention

Outcome Measures

Primary Outcomes (1)

  • Ulcer healing

Secondary Outcomes (2)

  • HIV viral load from genital ulcers

  • HIV viral load in semen

Interventions

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males presenting at the primary health care clinic with a genital ulcer
  • Age 18 years or older
  • Willing and able to give informed consent
  • Willing to be tested for HSV and HIV
  • Willing and able to comply with the study protocol including follow-up visits
  • Willing to accept therapy by chance

You may not qualify if:

  • Extensive ulceration
  • Ulceration \>1 month
  • History of adverse reaction to acyclovir
  • Taking suppressive therapy for genital herpes
  • History of renal insufficiency or proteinuria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Eloff Street Clinic

Johannesburg, Gauteng, South Africa

Location

Green Door, Alexandra Health Centre

Johannesburg, Gauteng, South Africa

Location

Related Publications (2)

  • Paz Bailey G, Sternberg M, Lewis DA, Puren A. Acute HIV infections among men with genital ulcer disease in South Africa. J Infect Dis. 2010 Jun 15;201(12):1811-5. doi: 10.1086/652785.

  • Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, Hawkes S, Nwanyanwu O, Ryan C, Lewis DA. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis. 2009 Oct 1;200(7):1039-49. doi: 10.1086/605647.

MeSH Terms

Conditions

HIV InfectionsUlcerHerpes Simplex

Interventions

Acyclovir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsHerpesviridae InfectionsDNA Virus InfectionsSkin Diseases, ViralSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

GuanineHypoxanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Gabriela Paz Bailey, MD

    Centers for Disease Control and Prevention

    PRINCIPAL INVESTIGATOR
  • David Lewis, MD

    STIRC, National Institute for Communicable Diseases (NICD), South Africa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2005

First Posted

September 14, 2005

Study Start

March 1, 2005

Primary Completion

March 1, 2009

Study Completion

July 1, 2011

Last Updated

September 11, 2012

Record last verified: 2012-09

Locations